ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06622 ZHAOKE OPHTH-B

Trading 03-25 14:07:24

1.880

-0.270

-12.56%

High2.140	Low1.880	Vol4.81M
Open2.140	D1 Closing2.150	Amplitude12.09%
Mkt Cap1.03B	Tradable Cap1.03B	Total Shares546.14M
T/O9.41M	T/O Rate0.88%	Tradable Shares546.14M
P/B0.47	ROE-10.65%	EPS-0.76
52wk High2.230	52wk Low1.200	P/E-2.48
Dividend0.00	Div.Yield0.00	ROA-7.61%

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"ZHAOKE OPHTH-B","latestPrice":1.88,"timestamp":1742882226641,"preClose":2.15,"halted":0,"volume":4808000,"delay":0,"floatShares":546139172,"shares":546139172,"eps":-0.7574128797561849,"marketStatus":"Trading","change":-0.27,"latestTime":"03-25 14:07:20","open":2.14,"high":2.14,"low":1.88,"amount":9407835,"amplitude":0.12093,"askPrice":1.9,"askSize":57500,"bidPrice":1.88,"bidSize":150500,"shortable":0,"etf":0,"ttmEps":-0.449111210679355,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1742890200000},"marketStatusCode":2,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.15,"openAndCloseTimeList":[[1742866200000,1742875200000],[1742878800000,1742889600000]],"volumeRatio":3.764775,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622/wiki","defaultTab":"wiki","newsList":[{"id":"1108867802","title":"Stock Track | Zhaoke Ophthalmology Plummets 6.51% Following Annual Loss of RMB237.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1108867802","media":"Stock Track","labels":["movement"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1108867802?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 09:33","pubTimestamp":1742866412,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  saw its stock price plummet by 6.51% in pre-market trading on Tuesday, following the release of its annual financial results. The sharp decline comes as investors react to the company's substantial loss for the year.According to the financial report, Zhaoke Ophthalmology posted a loss of RMB237.5 million for the fiscal year. This significant loss appears to have shaken investor confidence, leading to the sell-off. The company also reported annual revenue of RMB69.3 million,","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Zhaoke Ophthalmology Plummets 6.51% Following Annual Loss of RMB237.5 Million","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06622"],"gpt_icon":0},{"id":"2521776780","title":"BRIEF-Zhaoke Ophthalmology Posts Loss For Year RMB237.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2521776780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521776780?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 23:18","pubTimestamp":1742829505,"startTime":"0","endTime":"0","summary":"BRIEF-Zhaoke Ophthalmology Posts Loss For Year RMB237.5 MlnMarch 24 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK:LOSS FOR YEAR RMB237.5 MILLIONFurther company coverage: 6622.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","BK1583","06622","BK1574"],"gpt_icon":0},{"id":"2511565584","title":"Retail investors in Zhaoke Ophthalmology Limited (HKG:6622) are its biggest bettors, and their bets paid off as stock gained 22% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2511565584","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511565584?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 07:47","pubTimestamp":1739404023,"startTime":"0","endTime":"0","summary":"Key Insights Zhaoke Ophthalmology's significant retail investors ownership suggests that the key decisions are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6622/zhaoke-ophthalmology-shares/news/retail-investors-in-zhaoke-ophthalmology-limited-hkg6622-are","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","06622","BK1191","BK1583","BK1574"],"gpt_icon":0},{"id":"2503104303","title":"Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2503104303","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503104303?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 20:16","pubTimestamp":1736770586,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Mond","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["T10G.NZ","NZ50G.NZ","XAO.AU","XKO.AU","06622","BK1191","BK1574","NZ20C.NZ","BK1583","XJO.AU","BK1587"],"gpt_icon":0},{"id":"2503711263","title":"BRIEF-Zhaoke Ophthalmology Announces Distribution Agreement With AFT Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2503711263","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503711263?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 18:37","pubTimestamp":1736764635,"startTime":"0","endTime":"0","summary":"BRIEF-Zhaoke Ophthalmology Announces Distribution Agreement With AFT PharmaceuticalsJan 13 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK:ENTERING INTO DISTRIBUTION AGREEMENT WITH AFT PHARMACEUTICALSDIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O61OH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFT","BK1583","BK1574","BK1191","06622","BK1587"],"gpt_icon":0},{"id":"2503137530","title":"Zhaoke Ophthalmology Ltd - Entering Into Distribution- Agreement With AFT Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2503137530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503137530?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 17:41","pubTimestamp":1736761269,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O61OH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1587","06622","BK1191"],"gpt_icon":0},{"id":"2500198695","title":"Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2500198695","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500198695?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 18:02","pubTimestamp":1735898541,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology's  abbreviated new drug application  for NVK002  has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","06622","BK1574","BK1583","BK1191"],"gpt_icon":0},{"id":"2500942735","title":"BRIEF-Zhaoke Ophthalmology Says NMPA Acceptance Of New Drug Application For NVK002","url":"https://stock-news.laohu8.com/highlight/detail?id=2500942735","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500942735?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 19:42","pubTimestamp":1735818134,"startTime":"0","endTime":"0","summary":"Jan 2 (Reuters) - Zhaoke Ophthalmology Ltd   :   * NMPA ACCEPTANCE OF ABBREVIATED NEW DRUG- APPLICATION FOR NVK002 FOR TREATMENT OF- MYOPIA PROGRESSION IN CHILDRENFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","BK1191","06622","BK1583"],"gpt_icon":0},{"id":"2500949570","title":"Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2500949570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500949570?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 18:40","pubTimestamp":1735814451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nFWN3NW02O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06622","BK1587","BK1583","BK1191"],"gpt_icon":0},{"id":"2500991078","title":"Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991078","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500991078?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 13:53","pubTimestamp":1735797220,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology's  phase 3 trial of its TAB014 treatment for wet  age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.Shares jumped 7% during Thursday's trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1587","BK1583","BK1191","06622"],"gpt_icon":0},{"id":"2477016584","title":"Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2477016584","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477016584?lang=en_us&edition=full_marsco","pubTime":"2024-10-23 20:50","pubTimestamp":1729687820,"startTime":"0","endTime":"0","summary":"Top-line results from Zhaoke Ophthalmology's  phase III clinical trial of its NVK002 showed \"strong\" safety and high patient compliance, according to a Wednesday bourse disclosure.NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.The two-year trial involved 18 centers and enrolled 777 patients.Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.Price : $1.36, Change: $+0.030, Percent Change: +2.26%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","BK1587","BK1574","BK1191","BK4585","HKD","BK4023","06622","BK4588","BK1583"],"gpt_icon":0},{"id":"2470783908","title":"Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2470783908","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470783908?lang=en_us&edition=full_marsco","pubTime":"2024-09-26 18:01","pubTimestamp":1727344876,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  has completed the last patient visit for a phase III clinical trial of its TAB014 drug, a Thursday bourse filing said.The drug is intended for the treatment of wet  age-related macular degeneration.The trial involved around 57 centers and enrolled a total of 488 patients, according to the ophthalmic pharmaceutical company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1587","BK1574","06622","BK1191"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1198},{"period":"1month","weight":0.2011},{"period":"3month","weight":0.6797},{"period":"6month","weight":0.5693},{"period":"1year","weight":0.303},{"period":"ytd","weight":0.7917}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0182},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.2497},{"period":"1year","weight":0.4489},{"period":"ytd","weight":0.1917}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company’s products include innovative drugs and generic drugs. The Company ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.123174},{"month":2,"riseRate":0.25,"avgChangeRate":-0.139199},{"month":3,"riseRate":0.25,"avgChangeRate":0.002338},{"month":4,"riseRate":0.333333,"avgChangeRate":0.082275},{"month":5,"riseRate":0.25,"avgChangeRate":-0.097972},{"month":6,"riseRate":0.25,"avgChangeRate":0.066102},{"month":7,"riseRate":0.25,"avgChangeRate":-0.106219},{"month":8,"riseRate":0,"avgChangeRate":-0.064675},{"month":9,"riseRate":0.5,"avgChangeRate":-0.002156},{"month":10,"riseRate":0.25,"avgChangeRate":-0.065946},{"month":11,"riseRate":0.25,"avgChangeRate":0.017152},{"month":12,"riseRate":0.25,"avgChangeRate":0.00712}],"exchange":"SEHK","name":"ZHAOKE OPHTH-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZHAOKE OPHTH-B(06622) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZHAOKE OPHTH-B,06622,ZHAOKE OPHTH-B股票,ZHAOKE OPHTH-B股票老虎,ZHAOKE OPHTH-B股票老虎国际,ZHAOKE OPHTH-B行情,ZHAOKE OPHTH-B股票行情,ZHAOKE OPHTH-B股价,ZHAOKE OPHTH-B股市,ZHAOKE OPHTH-B股票价格,ZHAOKE OPHTH-B股票交易,ZHAOKE OPHTH-B股票购买,ZHAOKE OPHTH-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZHAOKE OPHTH-B(06622) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}